Tamar Taddei, MD
Professor of Internal Medicine (Digestive Diseases)Cards
Appointments
Additional Titles
Vice Chief, Faculty Development, Digestive Diseases
Chief, Digestive Diseases, VA Connecticut Healthcare System, VA Connecticut Health Care System
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Appointments
Additional Titles
Vice Chief, Faculty Development, Digestive Diseases
Chief, Digestive Diseases, VA Connecticut Healthcare System, VA Connecticut Health Care System
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Appointments
Additional Titles
Vice Chief, Faculty Development, Digestive Diseases
Chief, Digestive Diseases, VA Connecticut Healthcare System, VA Connecticut Health Care System
Contact Info
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
About
Titles
Professor of Internal Medicine (Digestive Diseases)
Vice Chief, Faculty Development, Digestive Diseases
Positions outside Yale
Chief, Digestive Diseases, VA Connecticut Healthcare System, VA Connecticut Health Care System
Biography
Dr. Taddei is Chief of Gastroenterology at VA Connecticut Healthcare System and Professor of Medicine (Digestive Diseases) and Vice Chief of Faculty Development (Digestive Diseases) at Yale School of Medicine. Her clinical interests focus on developing systems and programs to deliver outstanding multidisciplinary care to people with liver cancer. She directs the Liver Cancer Program at VA Connecticut Healthcare System and founded a VA regional tumor board serving Connecticut, Massachusetts, Rhode Island, and Vermont. Her research focuses on outcomes and clinical trials in cirrhosis and liver cancer. She is co-principal investigator of the Veterans Outcomes and Costs Associated with Liver disease (VOCAL) study group, the Statins and Cirrhosis - Reducing Events of Decompensation (SACRED) clinical trial, and the PREventing Liver Cancer Mortality through Imaging with Ultrasound vs. MRI (PREMIUM) clinical trial. Passionate about educating, mentoring and sponsoring the next generation, Dr. Taddei has been recognized with teaching awards for her dedication to the education and career advancement of medical students, residents, and fellows.
Appointments
Digestive Diseases
ProfessorPrimary
Other Departments & Organizations
- Cancer Prevention and Control
- Digestive Diseases
- Hepatology
- Internal Medicine
- Liver Center
- Lysosomal Disease & Inherited Metabolic Liver Disease Program
- Status of Women in Medicine Committee (SWIM)
- Viral Hepatitis Program
- Yale Cancer Center
- Yale Medicine
- Yale Ventures
- Yale-UPR Integrated HIV Basic and Clinical Sciences Initiative
Education & Training
- Fellow
- Yale University School of Medicine (2007)
- Resident
- Georgetown University Hospital (2004)
- MD
- Georgetown University School of Medicine (2000)
- BS
- Georgetown University (1992)
Research
Overview
Medical Subject Headings (MeSH)
Research at a Glance
Yale Co-Authors
Publications Timeline
Research Interests
Rajni Mehta, MPH
Amy Justice, MD, PhD
Catherine Mezzacappa, MD, MPH
Dhanpat Jain, MD
Mario Strazzabosco, MD, PhD
Pramod Mistry, MBBS, PhD, MA, MD
Liver Cirrhosis
Carcinoma, Hepatocellular
Delivery of Health Care
Digestive System Diseases
Publications
2024
Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchCitationsAltmetricConceptsIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidenceScreening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Mezzacappa C, Kim N, Vutien P, Kaplan D, Ioannou G, Taddei T. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open 2024, 7: e2420963. PMID: 38985470, PMCID: PMC11238019, DOI: 10.1001/jamanetworkopen.2024.20963.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsHepatitis C virus cureHepatitis C virusAssociated with improved overall survivalHepatocellular carcinoma diagnosisEarly-stage hepatocellular carcinomaImproved overall survivalOverall survivalHepatocellular carcinomaFollow-upHCC screeningCurative treatmentCumulative incidence of hepatocellular carcinomaDirect-acting antiviral (DAA) therapyCohort studyVeterans Affairs health care systemIncidence of hepatocellular carcinomaRisk of hepatocellular carcinomaCohort study of personsHepatitis C virus cirrhosisDiagnosis of hepatocellular carcinomaLikelihood of curative treatmentYears of follow-upHealth care systemHepatocellular carcinoma screeningHCV-related cirrhosisW31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis
Haque L, Fiellin D, Bryant K, Edelman E, Justice A, Lim J, Re V, Marshall B, Taddei T, Tate J, Tetrault J, Williams E, McGinnis K. W31 The Impact of Tobacco Use on Liver-Related Morbidity in Patients With Cirrhosis. Drug And Alcohol Dependence 2024, 260: 110649. DOI: 10.1016/j.drugalcdep.2023.110649.Peer-Reviewed Original ResearchIdentification of hepatic steatosis among persons with and without HIV using natural language processing
Torgersen J, Skanderson M, Kidwai-Khan F, Carbonari D, Tate J, Park L, Bhattacharya D, Lim J, Taddei T, Justice A, Re V. Identification of hepatic steatosis among persons with and without HIV using natural language processing. Hepatology Communications 2024, 8: e0468. PMID: 38896066, PMCID: PMC11186806, DOI: 10.1097/hc9.0000000000000468.Peer-Reviewed Original ResearchAltmetricMeSH Keywords and ConceptsConceptsImaging ReportingSteatotic liver diseaseHIV statusHepatic steatosisPrevalence of metabolic comorbiditiesImaging studiesVeterans Aging Cohort StudyCompare patient characteristicsPositive predictive valueAlcohol use disorderAging Cohort StudyIdentification of hepatic steatosisHIV infectionHepatitis BMetabolic comorbiditiesNatural language processing algorithmsRadiological studiesCohort studyPatient characteristicsClinical reviewLiver diseaseHIVPredictive valueUse disorderClinical image reportsMo1525 HIGH PREVALENCE OF BARIATRIC SURGERY AMONG PATIENTS PRESENTING WITH ALCOHOL-ASSOCIATED HEPATITIS
Thompson R, Narayanan P, Mistry P, Taddei T, Rabiee A. Mo1525 HIGH PREVALENCE OF BARIATRIC SURGERY AMONG PATIENTS PRESENTING WITH ALCOHOL-ASSOCIATED HEPATITIS. Gastroenterology 2024, 166: s-1679. DOI: 10.1016/s0016-5085(24)04319-1.Peer-Reviewed Original ResearchMo1477 DEVELOPMENT AND VALIDATION OF CASE-FINDING ALGORITHMS TO IDENTIFY CHOLANGIOCARCINOMA AND ITS SUBTYPES IN VETERANS HEALTH ADMINISTRATION DATA
Ferrante N, Hubbard R, Weinfurtner K, Mezina A, Newcomb C, Furth E, Bhattacharya D, Njei B, Taddei T, Singal A, Hoteit M, Park L, Kaplan D, Re V. Mo1477 DEVELOPMENT AND VALIDATION OF CASE-FINDING ALGORITHMS TO IDENTIFY CHOLANGIOCARCINOMA AND ITS SUBTYPES IN VETERANS HEALTH ADMINISTRATION DATA. Gastroenterology 2024, 166: s-1056. DOI: 10.1016/s0016-5085(24)02898-1.Peer-Reviewed Original ResearchSystemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights.
Rose M, Kennedy E, Abou-Alfa G, Finn R, Gade T, Kelley R, Taddei T, Gordan J. Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights. JCO Oncology Practice 2024, 20: 1035-1039. PMID: 38662970, DOI: 10.1200/op.24.00189.Peer-Reviewed Original ResearchAltmetricOrganizational and Implementation Factors Associated with Cirrhosis Care in the Veterans Health Administration
McCurdy H, Nobbe A, Scott D, Patton H, Morgan T, Bajaj J, Yakovchenko V, Merante M, Gibson S, Lamorte C, Baffy G, Ioannou G, Taddei T, Rozenberg-Ben-Dror K, Anwar J, Dominitz J, Rogal S. Organizational and Implementation Factors Associated with Cirrhosis Care in the Veterans Health Administration. Digestive Diseases And Sciences 2024, 69: 2008-2017. PMID: 38616215, DOI: 10.1007/s10620-024-08409-6.Peer-Reviewed Original ResearchConceptsVeterans Affairs (VA) medical centersCirrhosis careDashboard usePopulation management toolCare processesSurveillance ratesDepartment of Veterans Affairs (VA) medical centersFactors associated with high performanceVeterans Health AdministrationHCC surveillanceSpecialty carePerceived barriersData Warehouse dataHealth AdministrationImplementation evaluationLinear regression modelsCareGastroenterology serviceMedical CenterMultivariate modelRegression modelsQuality measuresVeteransRate differencesWarehouse dataSafety of naltrexone in patients with cirrhosis
Thompson R, Taddei T, Kaplan D, Rabiee A. Safety of naltrexone in patients with cirrhosis. JHEP Reports 2024, 6: 101095. PMID: 38961852, PMCID: PMC11220533, DOI: 10.1016/j.jhepr.2024.101095.Peer-Reviewed Original ResearchCitationsAltmetricConceptsDrug-induced liver injuryRoussel Uclaf Causality Assessment MethodAlcohol use disorderInitiation of naltrexoneSafety of naltrexoneUse disorderRetrospective studyDevelopment of drug-induced liver injuryRoussel Uclaf Causality Assessment Method scoreLiver injuryLiver diseaseRetrospective study of patientsTreatment of alcohol use disordersTreat alcohol use disorderLiver enzyme elevationAlcohol-related cirrhosisCohort of patientsAlkaline phosphatase elevationDiagnosis of cirrhosisStudy of patientsAssociated with developmentCausality Assessment MethodPrescribed naltrexoneDecompensated cirrhosisEnzyme elevationTransjugular Intrahepatic Portosystemic Shunt Linked to Increased Risk of Hepatocellular Carcinoma: A VA Matched Cohort Study
Bansal S, Taddei T, Wells R, Serper M, Bittermann T, Mahmud N, Kaplan D. Transjugular Intrahepatic Portosystemic Shunt Linked to Increased Risk of Hepatocellular Carcinoma: A VA Matched Cohort Study. Journal Of Clinical And Translational Hepatology 2024, 12: 534-538. PMID: 38779520, PMCID: PMC11106346, DOI: 10.14218/jcth.2023.00554.Peer-Reviewed Original Research
Academic Achievements and Community Involvement
honor Alvan R. Feinstein Award
Yale School of Medicine AwardYale School of MedicineDetails05/22/2017United Stateshonor Digestive Diseases Fellowship Teaching Award
Yale University AwardYale University School of Medicine, Section of Digestive DiseasesDetails06/21/2011United Stateshonor Best Teacher – YNHH Hospitalist Service
Yale University AwardYale-New Haven HospitalDetails12/01/2010United Stateshonor Samuel Kushlan Award for Clinical Excellence in Fellowship
Yale University AwardYale UniversityDetails06/30/2007United States
Clinical Care
Overview
Tamar H. Taddei, MD, cares for patients with digestive and liver diseases, including transplant recipients and patients with liver cancer. “As a clinician, it is extremely gratifying to be able to make a difference in an individual's life,” she says. In addition to managing her own clinical practice, Dr. Taddei directs liver cancer roundtable meetings, where practitioners take a team-based approach to providing the best care strategy at Smilow Cancer Hospital at Yale New Haven, and at the VA Connecticut Healthcare System in West Haven.
A professor of medicine (digestive diseases) at Yale School of Medicine and Chief of Gastroenterology at VA Connecticut Healthcare System, Dr. Taddei focuses her research on improving outcomes for patients with liver ailments and on early detection of liver tumors. “The field is interesting, dynamic and challenging,” she says. “The liver is an amazing organ.”
She is excited by effective drugs for hepatitis C which have cured many patients and reduced the risk of cirrhosis and liver cancer, but she is concerned with the growing incidence of fatty liver. “We need to focus on wellness—healthy diet and exercise—before we become ill,” she says.
Clinical Specialties
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks & Media
News
- July 29, 2024
Dr. Tamar Taddei on Yale Cancer Answers: Multidisciplinary Liver Cancer Care
- April 29, 2024
Dr. Tamar Taddei on Yale Cancer Answers
- February 19, 2024
AASLD Guidance on Liver Cancer Management
- August 02, 2023
Highlighting Gender-based Differences in Alcohol-associated Hepatitis
Get In Touch
Contacts
Yale School of Medicine
Department of Medicine (Digestive Diseases), PO Box 208019
New Haven, CT 06520-8019
United States
Administrative Support
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.